This research was supported by a grant from the National Natural Science Foundation of China [31700818, 82173121]; and it is also supported by the Medical Research Project of Innovation Capability Enhancement Plan of Xi’an [21YXYJ0107]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Hyldgaard JM, Jensen JB. The Inequality of Females in Bladder Cancer.APMIS. 2021;129:694–9. [DOI] [PubMed]
Schneider T, Zhao L, Zhu Z, Gabrielyan G, Xiao H, Fajardo ED, et al. The past, present, and future of immunotherapy for bladder tumors.Med Oncol. 2022;39:236. [DOI] [PubMed]
Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).Eur Urol. 2022;81:75–94. [DOI] [PubMed]
Mariappan P, Smith G. A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database.J Urol. 2005;173:1108–11. [DOI] [PubMed]
Holmäng S, Ströck V. Should follow-up cystoscopy in bacillus Calmette-Guérin-treated patients continue after five tumour-free years?Eur Urol. 2012;61:503–7. [DOI] [PubMed]
PéterÁ, Kliton J, Zsuzsa KS, Levente V, László G, Zoltán TN, et al. Trimodal, organ-preserving treatment of organ-confined, muscle-invasive bladder cancer.Magy Onkol. 2021;65:319–28. Hungarian.
Culine S, Harter V, Gravis G, Fléchon A, Chevreau C, Mahammedi H, et al.; VESPER Trial Investigators. Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial.Clin Genitourin Cancer. 2021;19:554–62. [DOI] [PubMed]
Advanced Bladder Cancer Meta-analysis Collaboration. Neoaf Adoptive cell therapy djuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis.Lancet. 2003;361:1927–34. [DOI] [PubMed]
Farina MS, Lundgren KT, Bellmunt J. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.Drugs. 2017;77:1077–89. [DOI] [PubMed]
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al.; KEYNOTE-045 Investigators. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.N Engl J Med. 2017;376:1015–26. [DOI] [PubMed] [PMC]
Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.N Engl J Med. 2020;383:1218–30. [DOI] [PubMed]
Abd El-Salam MA, Smith CEP, Pan CX. Insights on recent innovations in bladder cancer immunotherapy.Cancer Cytopathol. 2022;130:667–83. [DOI] [PubMed]
Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD-1 Inhibition.N Engl J Med. 2017;377:2500-1. [DOI] [PubMed] [PMC]
Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.Lancet Oncol. 2020;21:1353–65. [DOI] [PubMed]
Davis L, Tarduno A, Lu YC. Neoantigen-Reactive T Cells: The Driving Force behind Successful Melanoma Immunotherapy.Cancers (Basel). 2021;13:6061. [DOI] [PubMed] [PMC]
Mierke CT. Phenotypic Heterogeneity, Bidirectionality, Universal Cues, Plasticity, Mechanics, and the Tumor Microenvironment Drive Cancer Metastasis.Biomolecules. 2024;14:184. [DOI] [PubMed] [PMC]
Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA. Development of Immunotherapy Combination Strategies in Cancer.Cancer Discov. 2021;11:1368–97. [DOI] [PubMed] [PMC]
Hu H, Wang K, Jia R, Zeng ZX, Zhu M, Deng YL, et al. Current Status in Rechallenge of Immunotherapy.Int J Biol Sci. 2023;19:2428–42. [DOI] [PubMed] [PMC]
Balar AV, Castellano D, O’Donnell PH, Grivas P, Vuky J, Powles T, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.Lancet Oncol. 2017;18:1483–92. [DOI] [PubMed]
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al.; IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.Lancet. 2017;389:67–76. [DOI] [PubMed] [PMC]
Renner A, Burotto M, Valdes JM, Roman JC, Walton-Diaz A. Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?Ther Adv Urol. 2021;13:17562872211029779. [DOI] [PubMed] [PMC]
Schulz GB, Black PC. Combination therapies involving checkpoint-inhibitors for treatment of urothelial carcinoma: a narrative review.Transl Androl Urol. 2021;10:4014–21. [DOI] [PubMed] [PMC]
Daniel TM. Leon Charles Albert Calmette and BCG vaccine.Int J Tuberc Lung Dis. 2005;9:944–5. [PubMed]
Lugosi L. Results of the BCG vaccination in Hungary since 1929: evaluation of preventive and immunotherapeutic effectiveness.Orv Hetil. 1998;139:1563–70. Hungarian. [PubMed]
Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.J Urol. 1976;116:180–3. [DOI] [PubMed]
Han J, Gu X, Li Y, Wu Q. Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect.Biomed Pharmacother. 2020;129:110393. [DOI] [PubMed]
Smaldone MC, Jacobs BL, Smaldone AM, Hrebinko RL Jr. Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma.Urology. 2008;72:613–6. [DOI] [PubMed]
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma.Nature. 2014;507:315–22. [DOI] [PubMed] [PMC]
Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, et al. Neoantigen vaccine: an emerging tumor immunotherapy.Mol Cancer. 2019;18:128. [DOI] [PubMed] [PMC]
Gao Q, Liang WW, Foltz SM, Mutharasu G, Jayasinghe RG, Cao S, et al.; Fusion Analysis Working Group; Cancer Genome Atlas Research Network; Chen K, Lazar AJ, Fields RC, Wendl MC, Van Tine BA, Vij R, et al. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.Cell Rep. 2018;23:227–38.e3. [DOI] [PubMed] [PMC]
Smart AC, Margolis CA, Pimentel H, He MX, Miao D, Adeegbe D, et al. Intron retention is a source of neoepitopes in cancer.Nat Biotechnol. 2018;36:1056–8. [DOI] [PubMed] [PMC]
Bigot J, Lalanne AI, Lucibello F, Gueguen P, Houy A, Dayot S, et al. Splicing Patterns in SF3B1-Mutated Uveal Melanoma Generate Shared Immunogenic Tumor-Specific Neoepitopes.Cancer Discov. 2021;11:1938–51. [DOI] [PubMed]
Lang F, Schrörs B, Löwer M, Türeci Ö, Sahin U. Identification of neoantigens for individualized therapeutic cancer vaccines.Nat Rev Drug Discov. 2022;21:261–82. [DOI] [PubMed] [PMC]
Zheng Y, Fu Y, Wang PP, Ding ZY. Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer.Dis Markers. 2022;2022:8270305. [DOI] [PubMed] [PMC]
Rock KL, Reits E, Neefjes J. Present Yourself! By MHC Class I and MHC Class II Molecules.Trends Immunol. 2016;37:724–37. [DOI] [PubMed] [PMC]
Gupta RG, Li F, Roszik J, Lizée G. Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches.Cancer Discov. 2021;11:1024–39. [DOI] [PubMed] [PMC]
Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.Nat Med. 2013;19:747–52. [DOI] [PubMed] [PMC]
Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle.Immunity. 2013;39:1–10. [DOI] [PubMed]
Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.J Immunol. 2005;174:2591–601. [DOI] [PubMed] [PMC]
Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, et al. Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer.Cell. 2020;181:1612–25.e13. [DOI] [PubMed] [PMC]
Lo AA, Wallace A, Oreper D, Lounsbury N, Havnar C, Pechuan-Jorge X, et al. Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies.J Immunother Cancer. 2021;9:e003001. [DOI] [PubMed] [PMC]
Nagaoka K, Sun C, Kobayashi Y, Kanaseki T, Tokita S, Komatsu T, et al. Identification of Neoantigens in Two Murine Gastric Cancer Cell Lines Leading to the Neoantigen-Based Immunotherapy.Cancers (Basel). 2021;14:106. [DOI] [PubMed] [PMC]
Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers.Science. 2015;350:1387–90. [DOI] [PubMed] [PMC]
Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival.Genome Res. 2014;24:743–50. [DOI] [PubMed] [PMC]
Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.Oncotarget. 2016;7:13587–98. [DOI] [PubMed] [PMC]
Matsushita H, Sato Y, Karasaki T, Nakagawa T, Kume H, Ogawa S, et al. Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma.Cancer Immunol Res. 2016;4:463–71. [DOI] [PubMed]
McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.Science. 2016;351:1463–9. [DOI] [PubMed] [PMC]
Evans RA, Diamond MS, Rech AJ, Chao T, Richardson MW, Lin JH, et al. Lack of immunoediting in murine pancreatic cancer reversed with neoantigen.JCI Insight. 2016;1:e88328. [DOI] [PubMed] [PMC]
Li L, Goedegebuure SP, Gillanders WE. Preclinical and clinical development of neoantigen vaccines.Ann Oncol. 2017;28:xii11–7. [DOI] [PubMed] [PMC]
Aldous AR, Dong JZ. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.Bioorg Med Chem. 2018;26:2842–9. [DOI] [PubMed]
Liang X, Li D, Leng S, Zhu X. RNA-based pharmacotherapy for tumors: From bench to clinic and back.Biomed Pharmacother. 2020;125:109997. [DOI] [PubMed]
Leko V, McDuffie LA, Zheng Z, Gartner JJ, Prickett TD, Apolo AB, et al. Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer.J Immunol. 2019;202:3458–67. [DOI] [PubMed] [PMC]
Lu HZ, Wang DK, Wang Z. Correlation analysis of the prognosis of HPV positive oropharyngeal cancer patients with T cell infiltration and neoantigen load.Yi Chuan. 2019;41:725–735. Chinese. [DOI] [PubMed]
Xu P, Luo H, Kong Y, Lai WF, Cui L, Zhu X. Cancer neoantigen: Boosting immunotherapy.Biomed Pharmacother. 2020;131:110640. [DOI] [PubMed]
Xu R, Du S, Zhu J, Meng F, Liu B. Neoantigen-targeted TCR-T cell therapy for solid tumors: How far from clinical application.Cancer Lett. 2022;546:215840. [DOI] [PubMed]
Aparicio C, Belver M, Enríquez L, Espeso F, Núñez L, Sánchez A, et al. Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells.Int J Mol Sci. 2021;22:11781. [DOI] [PubMed] [PMC]
Pan D, Tang Y, Tong J, Xie C, Chen J, Feng C, et al. An antibody-drug conjugate targeting a GSTA glycosite-signature epitope of MUC1 expressed by non-small cell lung cancer.Cancer Med. 2020;9:9529–40. [DOI] [PubMed] [PMC]
Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy.Science. 2018;359:1355–60. [DOI] [PubMed]
Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy.Science. 2015;348:69–74. [DOI] [PubMed]
Zhao W, Wu J, Chen S, Zhou Z. Shared neoantigens: ideal targets for off-the-shelf cancer immunotherapy.Pharmacogenomics. 2020;21:637–45. [DOI] [PubMed]
Klebanoff CA, Wolchok JD. Shared cancer neoantigens: Making private matters public.J Exp Med. 2018;215:5–7. [DOI] [PubMed] [PMC]
Xu H, Zheng X, Zhang S, Yi X, Zhang T, Wei Q, et al. Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma.Mol Cancer. 2021;20:159. [DOI] [PubMed] [PMC]
Zheng X, Xu H, Yi X, Zhang T, Wei Q, Li H, et al. Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine.Mol Cancer. 2021;20:160. [DOI] [PubMed] [PMC]
Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, et al. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.Cell. 2020;183:347–62.e24. [DOI] [PubMed]
Marron TU, Saxena M, Bhardwaj N, Meseck M, Rubinsteyn A, Finnigan J, et al. Abstract LB048: An adjuvant personalized neoantigen peptide vaccine for the treatment of malignancies (PGV-001).Cancer Res. 2021;81:LB048. [DOI]
Wang C, Yu M, Zhang W. Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective.Cancer Lett. 2022;550:215945. [DOI] [PubMed]
Zaidi N. Can Personalized Neoantigens Raise the T Cell Bar?Cell. 2020;183:301–2. [DOI] [PubMed] [PMC]
Romero JM, Jiménez P, Cabrera T, Cózar JM, Pedrinaci S, Tallada M, et al. Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer.Int J Cancer. 2005;113:605–10. [DOI] [PubMed]
Cabrera T, Pedrajas G, Cozar JM, Garrido A, Vicente J, Tallada M, et al. HLA class I expression in bladder carcinomas.Tissue Antigens. 2003;62:324–7. [DOI] [PubMed]
Pearlman AH, Hwang MS, Konig MF, Hsiue EH, Douglass J, DiNapoli SR, et al. Targeting public neoantigens for cancer immunotherapy.Nat Cancer. 2021;2:487–97. [DOI] [PubMed] [PMC]
